Tumors of Kidney and Urinary Tract Flashcards

1
Q

Renal Neoplasms

A

• Benign tumors

♦ Renal papillary adenoma

♦ Angiomyolipoma

♦ Oncocytoma

• Malignant tumors

♦ Renal cell carcinoma

♦ Wilms tumor

♦ Urothelial (transitional cell) carcinoma of renal pelvis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Renal Papillary Adenoma

A
  1. Common (up to 22% of patients at autopsy)
  2. Gross findings
    a. Small (less than or equal to 1.5 cm)
    b. Pale yellow-gray, discrete, well circumscribed nodule in the cortex
    i. May be multiple
  3. Microscopic findings
    a. Papillary or tubular architecture
    b. Bland, cuboidal nuclei without atypia (low grade)
    i. No obvious nucleoli, mitoses or significant pleomorphism
    c. Well circumscribed, but no capsule or desmoplastic response
  4. Behavior
    a. Benign – no metastasis or progression
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q
A

Renal Papillary Adenoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Angiomyolipoma

A
  1. Relatively rare tumor. Most cases are sporadic, not associated with genetic syndrome. 2. Minority of cases associated with tuberous sclerosis (brain lesions causing epilepsy/mental retardation, skin abnormalities, variety of benign neoplasms)
    a. 25-50% of patients with tuberous sclerosis have angiomyolipoma
  2. Usually benign behavior, rarely metastasizes
    a. Patients may have spontaneous hemorrhage of tumor
  3. Gross findings
    a. Variable appearance

– Tan to brown, may have areas of hemorrhage and yellow adipose tissue

  1. Microscopic findings
    a. Composed of variable amounts of blood vessels, smooth muscle and fat
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q
A

Angiomyolipoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q
A

Angiomyolipoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q
A

Angiomyolipoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Oncocytoma

A
  1. Represents 5-15% of all primary renal tumors
  2. Benign behavior
  3. Gross findings
    a. Solid, mahogany brown
    b. May have a central scar
    c. May be large (tumors up to 12 cm reported)
  4. Microscopic findings
    a. Nests of cells with abundant granular eosinophilic cytoplasm and bland nuclei (no significant atypia, necrosis or mitoses)
    i. Cells contain numerous mitochondria
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q
A

Oncocytoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q
A

Oncocytoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Renal Cell Carcinoma

A
  1. Origin from renal cortical tubules; account for 85% of primary renal malignancies
  2. Biologic behavior related to:
    a. Tumor size - Tumors less than 3 cm in diameter rarely metastasize; tumors over 3 cm diameter may metastasize
    b. Pathologic stage – Penetration through renal capsule, involvement of surrounding perinephric fat, invasion into vascular structures, and lymph node metastases are all associated with worse prognosis
    c. Tumor grade – Higher grade = more aggressive behavior
  3. Clinical features:
    a. Affects adults (usually older than 50 years); males more commonly affected than females
    b. Classic triad of symptoms: (Seen only in 10% of cases)
    i. Costovertebral angle pain
    ii. Palpable mass
    iii. Hematuria (most common symptom, often microscopic)
    c. Paraneoplastic syndrome: Polycythemia (due to secretion of erythropoietin)
    d. 25% of patients have metastases at time of diagnosis (most often to lung or bone; ~ 10% metastasize to the opposite kidney)
    e. Localized Disease Treatment: Surgical
    i. Radical nephrectomy

– Removal of entire kidney and surrounding perinephric fat up to Gerota’s fascia (large tumors, or tumors extending outside of the kidney)

ii. Partial nephrectomy – Indicated for some tumors <7 cm and confined to kidney
a. Partial nephrectomy is “nephron sparing” and better choice for patients with underlying kidney disease to preserve renal function
f. Metastatic Disease Treatment: Chemotherapy - Most RCC does not respond to standard chemotherapy
i. Newer agents directly target VEGF, tyrosine kinases, mTOR
ii. Immunotherapy – IL-2, interferon-alpha (significant side effects)
g. Prognosis – Depends on Stage. 5 year survival:
i. Stage I (< 7cm, confined to kidney) - 95%
ii. Stage II (> 7cm, confined to kidney) – 82%
iii. Stage III (Renal vein invasion or in perinephric fat) – 64%
iv. Stage IV (lymph node or distant metastases) – 23%
4. Frequent cytogenetic abnormalities in renal cell carcinoma:
a. Clear-cell carcinoma: chromosome 3p deletion
i. Often includes loss of the Von Hippel-Lindau tumor suppresser gene
ii. May result in promotion of tumor angiogenesis through activation of VEGF
b. Papillary carcinoma: trisomy chromosome 7
i. May include mutation of MET proto-oncogene, which encodes a tyrosine kinase receptor for hepatocyte growth factor
5. Pathology
a. Gross findings: Nodular mass, frequently bright yellow, with areas of hemorrhage and necrosis
b. Microscopic findings:
i. Clear cell carcinoma (70-80%): Cells have clear cytoplasm (containing lipid and/or glycogen), arranged in nests and sheets along delicate fibrovascular network
a. May have bland nuclear features, except for highgrade tumors.
ii. Papillary carcinoma (10-15%): Cuboidal or low columnar cells arranged in papillary formations, may have prominent macrophages, often multifocal.
iii. Others: Chromophobe carcinoma, Collecting duct carcinoma, Xp11 translocation carcinoma
6. Pattern of spread
a. Invasion through renal capsule into perinephric fat
b. Invasion of renal vein with proximal spread along inferior vena cava (may spread by this route up into right atrium of the heart)
c. Lymph node metastases: Renal hilum, para-aortic
d. Distant metastases: Adrenal gland, liver, lungs, brain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q
A

Renal Cell Carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q
A

Renal Cell Carcinoma

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q
A

Renal Cell Carcinoma - Clear Cell Type

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q
A

Renal Cell Carcinoma - Clear Cell Type

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q
A

Renal Cell Carcinoma - Papillary

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q
A

Renal Cell Carcinoma - Papillary

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q
A

Renal Cell Carcinoma - Chromophobe

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Renal Cell Carcinoma Grades

A
20
Q
A

RCC - Sarcomatoid Dedifferentiation

21
Q

RCC - Sarcomatoid Dedifferentiation

A
22
Q

Wilms Tumor (Nephroblastoma)

A
  1. Malignant renal tumor of children (generally 2-5 years old); 4th most common pediatric malignancy in United States
  2. Chromosomal abnormality: Most common is mutation of a portion of short arm of chromosome 11 that codes for the WT1 gene (Wilms tumor associated gene)
    a. Germline WT1 mutations are associated with several genetic syndromes:
    i. WAGR syndrome: Wilms tumor, aniridia, genital anomalies and mental retardation
    ii. Denys-Drash syndrome: Wilms tumor, gonadal dysgenesis, early-onset nephropathy leading to renal failure
  3. Clinical features
    a. Usually presents as abdominal mass
    i. One of three important intra-abdominal mass-lesion malignancies of infancy/childhood (the others being hepatoblastoma of liver and neuroblastoma of adrenal)
    b. Other symptoms: Abdominal pain, hematuria, intestinal obstruction, hypertension
    c. 5-10% bilateral tumors
    i. Patients with bilateral Wilms present earlier
    ii. Often caused by germline mutation in Wilms tumorpredisposing genes
    d. Treatment:
    i. May include combined surgical, radiation therapy and chemotherapy
    e. Prognosis: Depends on tumor stage, and histologic appearance - presence/absence of anaplasia (see below)
    i. Favorable histology (no anaplasia)

– 4 year survival 80- 90%

ii. Unfavorable histology (anaplastic)

– 4 year survival varies from 80% (stage I) to 50% (stage IV)

  1. Pathology
    a. Gross findings: Nodular, gray to gray-white, soft, fleshy mass
    b. Microscopic findings: Represents malignancy of primitive renal blastema, with epithelial and stromal components (triphasic pattern)
    i. Primitive blastema - Small, dark, undifferentiated cells
    ii. Epithelial component - Abortive tubules and glomeruli
    iii. Stroma - May have heterologous elements (cartilage, muscle, bone)
    c. Anaplasia: Specifically defined in Wilms tumor by presence of tumor cell pleomorphism, hyperchromatic nuclei and abnormal mitotic figures
    i. Anaplasia is a poor prognostic indicator; correlates with more aggressive behavior due to resistance to chemotherapy
    d. Nephrogenic rests: Clusters of primitive cells seen in the renal parenchyma adjacent to Wilms tumors; may be a precursor lesion
    i. Present in up to 40% of unilateral Wilms, and 100% of bilateral Wilms tumor patients
23
Q
A

Wilms Tumor

24
Q
A

Wilms Tumor

25
Q
A

Wilms Tumor - Anaplasia

26
Q

Additional Malignant Renal Tumors of Childhood

A
  • clear cell carcinoma
  • rhabdoid tumor
27
Q

Urothelial Carcinoma

A
  1. Origin in urothelium lining the renal pelvis
  2. Clinical features:
    a. Represents 5-10% of primary renal tumors
    b. Occurs in adults
    c. Frequently associated with urothelial carcinoma or dysplasia elsewhere in the urinary system, particularly in the bladder (“field effect” of carcinogenesis)
    i. 50% of patients may have pre-existing or concomitant bladder tumor
    d. Patients present with hematuria, urinary obstruction, hydronephrosis, flank pain
    i. Often comes to clinical attention earlier vs renal cell carcinoma due to location and tendency to cause obstructive symptoms
  3. Pathology
    a. Gross findings
    i. Papillary – Exophytic mass with papillary fronds
    ii. Flat lesion – Reddened or granular appearance
    b. Microscopic findings
    i. Papillary – Papillary fronds with vascular cores lined by a proliferation of malignant urothelial cells
    ii. Flat – No papillary growth pattern, cells show malignant features (high N:C ratios, hyperchromasia, pleomorphism), disordered maturation
    iii. Cytology of neoplastic cells ranges from relatively bland (low-grade) to very malignant (high grade)
    - Low grade lesions: Rarely invade (but may recur)
    - High grade lesions: Often invade
    c. Appearance similar to urothelial carcinoma in ureter and urinary bladder
  4. Behavior and prognosis
    a. Infiltrates adjacent calyces and renal parenchyma
    b. Prognosis – depends on grade, depth of penetration through urothelial wall, presence/absence of metastases
28
Q
A

Urothelial Carcinoma

29
Q
A

Normal Urothelium

30
Q
A

Normal Renal Pelvis

31
Q
A

Papillary Urothelial Carcinoma

32
Q
A

Papillary Urothelial Carcinoma Low Grade

33
Q
A

Papillary Urothelial Carcinoma High Grade

34
Q
A

Papillary Urothelial Carcinoma - in situ

35
Q
A

Papillary Urothelial Carcinoma Invasive

36
Q
A

Papillary Urothelial Carcinoma Invasive High Grade

37
Q
A

Papillary Urothelial Carcinoma Ureter

38
Q

Urinary Bladder Neoplasms

A

I. Incidence

A. Bladder cancer accounts for 5% of cancers and 3% cancer deaths in US

B. Higher incidence in males

  1. Urothelial carcinoma: Male:female ratio of 3:1; Squamous cell carcinoma: Male:female ratio of 3:2

C. 80% of patients are between 50 and 80 years

II. Epidemiology and Pathogenesis

A. Cigarette smoking

  1. Most important factor, increases risk by 3 to 7 fold
  2. Associated with 50-80% of all bladder cancers

B. Chemical carcinogens: 2-naphthylamine and related arylamines

C. Infectious agents

  1. Schistosoma haematobium – Parasite; associated with squamous cell carcinoma
    a. Endemic areas – Egypt, Sudan

D. Other risk factors: Cyclophosphamide, long-term analgesic use, radiation exposure

III. Clinical Diagnosis

A. Signs and symptoms: Hematuria, dysuria

B. Goal: Early detection and treatment

  1. Cystoscopy with biopsy
  2. Urine cytology
    a. Best for detection of high grade malignancy
    b. Difficult to distinguish low grade carcinoma from reactive urothelium

IV. Neoplasms – Classification

A. Benign bladder tumors (rare)

  1. Leiomyoma - Most common
  2. Urothelial papilloma (benign, very rare)

B. Malignant bladder tumors (more common)

  1. Urothelial carcinoma – 90% of all bladder tumors; both papillary and flat lesions with similar gross and microscopic features as renal pelvis, as discussed above (section D3) a. Papillary lesions
    i. Urothelial neoplasm of low malignant potential
    ii. Papillary urothelial carcinoma, low grade aa. 10% risk of invasion iii. Papillary urothelial carcinoma, high-grade aa. 80% risk of invasion
    b. Flat lesions
    i. Dysplasia (low grade, no risk of invasion)
    ii. Carcinoma in situ (CIS) (high-grade) aa. Increased risk for progression to invasive carcinoma
  2. Squamous cell carcinoma
    a. Represents 3-7% of all malignant bladder tumors
    b. Arise in a background of squamous metaplasia, usually associated with chronic inflammation/infection
    c. Well known association with schistosomiasis
    d. Morphologic appearance similar to squamous cell carcinoma occurring elsewhere
    e. Treatment – Radical cystectomy
  3. Adenocarcinoma (rare)
    a. Similar appearance to colonic adenocarcinoma
    b. May arise from urachal remnant
    c. Treatment – Radical cystectomy +/- radiation
  4. Small cell carcinoma (SCC) (rare, aggressive)
    a. Poorly differentiated appearance (scant cytoplasm, high N:C ratios)
    b. Similar in appearance and behavior to pulmonary small cell carcinoma
    c. Treatment
    i. Localized disease - Aggressive combined modality (chemotherapy + radical cystectomy and/or radiation)
    ii. Disseminated disease – Systemic chemotherapy
  5. Sarcomas (rare)
    a. Embryonal rhabdomyosarcoma – Malignant tumor of urinary bladder in children
    b. Leiomyosarcoma - Adults 6. Lymphoma (rare)

V. Staging

A. Depends on depth/extent of invasionB. AJCC criteria: see image

B. Invasion of muscularis propria (T2) is an important prognostic indicator; requires more aggressive therapy (usually cystectomy)

VI. Clinical Course and Treatment – Urothelial Carcinoma

A. 60% of neoplasms are single, 70% are localized to the bladder

B. Tendency to develop new tumors after excision; recurrences may be of higher grade C. Prognosis depends on histologic grade and stage of progression

  1. Papilloma, papillary urothelial neoplasms of low malignant potential and low grade papillary urothelial carcinoma all have >90% 10 year survival
    a. Less than 10% progress to higher grade
  2. High grade papillary urothelial neoplasms – increased propensity to invade and metastasize a. Invasive urothelial carcinoma is almost always high grade
  3. Treatment
    a. Transurethral resection: Low-grade, non-invasive papillary lesions
    b. Topical immunotherapy: Carcinoma in situ, high-grade noninvasive lesions, lesions with limited (lamina propria) invasion
    i. Agent used: Bacillus Calmette-Guerin (BCG) – attenuated form of tuberculous bacillus ii. Causes a granulomatous inflammatory response
    c. Radical cystectomy: Muscularis propria (T2) invasion or higher, CIS or high-grade lesions refractory to BCG therapy
    d. Chemotherapy: Advanced disease
39
Q
A

Bladder Cancer in situ

40
Q
A

Squamous Cell Carcinoma

41
Q
A

Small Cell Carcinoma

42
Q

Bladder Carcinoma Stages

A
43
Q
A

Adenocarcinoma

44
Q
A

Urothelial Carcinoma Invasive

45
Q
A

Papillary Urothelial Carcinoma

46
Q
A

Papillary Urothelial Carcinoma Bladder